Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

Scarpato, Salvatore; Antivalle, M.; Favalli, Ennio Giulio; Nacci, Francesca; Frigelli, S.; Bartoli, Francesca; Bazzichi, Laura; Minisola, Giovanni; Cerinic, M Matucci

doi:10.1093/rheumatology/kep354

Cited by 69 publications

(89 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, GOL is the only anti-TNF therapy that can be administered as either an SC injection (monthly) or an IV infusion (over 30 min every 8 weeks). Patients often have preferences for mode and frequency of treatment administration for biologic therapies 9,10 . Patient involvement in determining treatment decisions has been shown to improve treatment satisfaction 26 and also efficacy outcomes 27 .…”

Section: Discussionmentioning

confidence: 99%

“…Some patients are unable or unwilling to self-administer SC biologics at home and may prefer IV biologics. In a previous study, patients with RA receiving IV therapy generally preferred to receive their medication in a medical facility 9 , and in 1 study, patients cited "safety of the hospital administration" and "reassuring effect of the doctor's presence" as The American College of Rheumatology, the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network (SPARTAN) treatment recommen-reasons for preferring to receive their medication in a healthcare facility 10 . Some patients also prefer the less frequent dosing interval for IV therapies compared with SC therapies 10 .…”

mentioning

confidence: 99%

“…In a previous study, patients with RA receiving IV therapy generally preferred to receive their medication in a medical facility 9 , and in 1 study, patients cited "safety of the hospital administration" and "reassuring effect of the doctor's presence" as The American College of Rheumatology, the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network (SPARTAN) treatment recommen-reasons for preferring to receive their medication in a healthcare facility 10 . Some patients also prefer the less frequent dosing interval for IV therapies compared with SC therapies 10 . The approved dosing frequency for IV GOL in patients with RA is every 8 weeks after an induction regimen of 2 doses 4 weeks apart 3 compared with monthly injections for SC GOL 2 and more frequent administrations (weekly or biweekly) for other SC anti-TNF therapies 11,12 .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study

Deodhar

Reveille²,

Harrison³

et al. 2017

J Rheumatol

100

View full text Add to dashboard Cite

Objective.To evaluate the safety and efficacy of intravenous golimumab (GOL) in patients with active ankylosing spondylitis (AS).Methods.In a phase III, randomized, double-blind, placebo (PBO)-controlled trial, 208 patients were randomized (1:1) to intravenous (IV) infusions of GOL 2 mg/kg (n = 105) at weeks 0, 4, 12, and every 8 weeks, or PBO (n = 103) at weeks 0, 4, and 12, with crossover to GOL at Week 16. The primary endpoint was ≥ 20% improvement from baseline in the Assessment of Spondyloarthritis International Society Criteria (ASAS20) at Week 16. Secondary endpoints included ASAS40, ≥ 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50), and change in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16. Safety was monitored through Week 28.Results.Significantly greater proportions of GOL-treated patients had ASAS20 response at Week 2 (37.1% vs 19.4%; p = 0.005) and at Week 16 (73.3% vs 26.2%; p < 0.001). At Week 16, 41.0% of those receiving GOL achieved BASDAI50 compared with 14.6% of those taking PBO (p < 0.001), and the GOL group had greater mean improvement in BASFI (−2.4 vs −0.5; p < 0.001). Through Week 16, 23.3% of patients in the PBO group and 32.4% of patients in the GOL group had ≥ 1 adverse event (AE); infections being the commonest type of AE. Through Week 28, two GOL-treated patients had a serious AE.Conclusion.GOL 2 mg/kg administered IV at weeks 0, 4, and every 8 weeks significantly reduced the signs and symptoms of AS in adults. AE were consistent with other antitumor necrosis factor therapies, with no new safety signals (Clinicaltrials.gov: NCT02186873).

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study

Deodhar

Reveille²,

Harrison³

et al. 2017

J Rheumatol

100

View full text Add to dashboard Cite

show abstract

“…Although there are other good quality studies that examine patients' preferences [18][19][20][21][22][23][24], none are RCTs. For example, one study measured preferences of IBD patients for two anti-TNF agents in terms of their mode of administration by using hypothetical scenarios [18].…”

Section: Discussionmentioning

confidence: 99%

“…There are in fact few studies where patients' preferences or acceptance for IV and SC drug administration are primary outcomes [18][19][20][21][22][23][24]. A good example is the report by Barbee et al (2013) [19] in which patients with MM who received at least one dose each of IV and SC bortezomib were asked via a questionnaire about their preference for route of drug delivery; 68% preferred SC whilst 25% favoured IV.…”

Section: Introductionmentioning

confidence: 99%

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Stoner

Harder

Fallowfield

et al. 2014

Patient

121

102

View full text Add to dashboard Cite

show abstract

Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment

Burnett

Regier

Feldman

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To examine parents' preferences for drug treatments and health outcomes in juvenile idiopathic arthritis (JIA) and identify demographic and health-related factors that significantly impact choice. Methods. A discrete choice experiment was conducted with 105 parents of children with JIA who were cared for by a rheumatologist at The Hospital for Sick Children in Canada. Attributes evaluated included "drug treatment," "child reported pain from arthritis," "participation in daily activities," "side effects," "days missed from school," and "cost to you." Multinomial logit regression was used to estimate the relative importance of each attribute level and interaction term. Results. Parents made tradeoffs between characteristics of the drug treatments and health outcomes. "Participation in daily activities" was the most important attribute, followed by "child reported pain from arthritis" and "cost to you." Parents of children with longer disease durations had stronger preferences for improved participation in daily activities, whereas parents of older JIA patients had stronger preferences for improved control of pain. Conclusion. Parents of children with JIA demonstrated strong preferences for treatments that reduce pain and improve daily functioning regardless of the associated side effects, level of responsibility required for drug administration, and days missed from school. Parents of children with longer disease durations and those who had been prescribed aggressive therapies had a greater preference for treatment effectiveness. These findings support the need for considering parental preferences in decisions regarding the choice of treatment for JIA.

show abstract

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

Cited by 69 publications

References 19 publications

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment

Contact Info

Product

Resources

About